ClinicalTrials.gg
Active, not recruitingNCT04711252SERENA-4Updated Sep 28, 2026

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

A Phase 3 interventional study of AZD9833 and Anastrozole in ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 263 sites in 27 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Primary completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,371
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Neoplasm Metastasis by AstraZeneca — 6 open to participants now, 23 under way, 14 of them phase 3. Neoplasm Metastasis · AstraZeneca.

Enrollment
Largest of 55
1,371 · median 102
Started
2021
with 5 others
Phase 3
19 of 60
4 open now
Primary completion
2026-06
later than 12 of 22 live
Registered
45th of 60
by date

Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one has the largest enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2021, is one of 19 in phase 3, reaches primary completion later than 12 of the 22 other live ones, and was the 45th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 60 studies in Neoplasm Metastasis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neoplasm Metastasis by AstraZeneca, or all of them as a file.
02

Study summary

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

INFORMATION FOR TRIAL PARTICIPANTS

In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment.

Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.

Read the detailed description

A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 (next generation oral SERD) in combination with palbociclib versus anastrozole in combination with palbociclib for the treatment of patients with ER-positive breast cancer. The goal of the study is to demonstrate superiority of AZD9833 over anastrozole in the context of combination with palbociclib in first line setting.

INFORMATION FOR TRIAL PARTICIPANTS

Researchers are looking for a better way to treat breast cancer.

In people with cancer, some cells have grown out of control to form tumours.

The trial drugs palbociclib, camizestrant, and anastrozole are designed to work by blocking the cancer's ability to grow. Camizestrant is also called AZD9833. Palbociclib and anastrozole are already available as treatments for people with certain type of breast cancer.

In this trial, the researchers want to find out how well taking camizestrant with palbociclib, or anastrozole with palbociclib, works in participants with breast cancer that has ER proteins but does not have overexpression of HER2 protein.

The researchers will look at which trial treatments help the participants live longer with cancer before it gets worse.

The trial will split participants into 2 groups:

  • Participants in Group 1 will take camizestrant, palbociclib, and a placebo matched with anastrazole.
  • Participants in Group 2 will take anastrozole, palbociclib, , and a placebo matched with camizestrant.

A placebo looks like a treatment but does not have any medicine in it.

A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.

The participants will take their trial treatments in periods called "cycles". Each cycle will last 28 days. During each cycle, the participants will take:

  • camizestrant or anastrozole once daily by mouth
  • palbociclib once daily by mouth for 21 days. Then, they will not take any palbociclib for 7 days

Some participants will also get either goserelin or leuprorelin once every month. Participants could get goserelin or leuprorelin if:

  • They are medically determined yet to reach menopause status
  • They are male

They will get this treatment as an injection under the skin or into a muscle. Goserelin and leuprorelin work by decreasing the amount of sex hormones made by the body which will lead to reduction of ER production. This can help stop breast cancer from growing.

Participants will take trial treatment until the cancer gets worse or they leave the trial.

Participants will visit their trial site several times throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.

03

Conditions studied

  • ER-Positive HER2-Negative Breast Cancer

Keywords

  • Metastatic
  • Breast Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Breast Diseases
  • Skin Diseases
  • Hormones, Hormone Substitutes, and Hormone
  • Physiological Effects of Drugs
  • Randomised
  • Multicentre
  • Double-Blind
  • Phase III
  • AZD9833
  • Next Generation Oral SERD
  • Anastrozole
  • Palbociclib
  • Antagonists
  • Antineoplastic Agents
  • Estrogen Receptor Antagonists
  • Hormone Antagonists
  • camizestrant
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Full list of inclusion criteria

  • Pre-/peri-menopausal women or men can be enrolled if amenable to be treated with concomitant, approved LHRH agonists for the duration of the study treatment.
  • De novo Stage 4 disease, or recurrence from early stage disease after at least 24 months of standard endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week is required after the last dose of tamoxifen prior to randomisation.
  • or cytologically documented diagnosis of ER+, -negative breast cancer based on local laboratory results.
  • Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or ER+ disease.
  • as defined per v.1.1 OR at least one lytic or mixed (lytic + sclerotic) bone lesion with a soft tissue component that can be assessed by CT or MRI.
  • performance status of 0 or 1.
  • Adequate organ and marrow function.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

INFORMATION FOR TRIAL PARTICIPANTS

Participants can join the trial if they:

  • Have breast cancer that cannot be treated with surgery or radiation
  • Have breast cancer that has already spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of a standard endocrine treatment
  • Have ER proteins but not overexpression of HER2 protein in their tumors
  • Have never received any type of cancer therapy that affects the whole body for advanced breast cancer
  • Are able to do their daily activities

Exclusion criteria

EXCLUSION CRITERIA

Full list of exclusion criteria

  • Previous or adjuvant treatment with an AI treatment +/- CDK4/6 inhibitor with disease recurrence while on or within 12 months of completing treatment.
  • Prior exposure to AZD9833, other SERDs/endocrine agents or fulvestrant.
  • Participation in another clinical study with a study treatment or investigational medicinal device administered in the last 4 weeks prior to randomization or concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term and/or impending visceral crisis
  • Known active uncontrolled or symptomatic , carcinomatous meningitis, or .
  • Any and symptomatic heart disease .
  • Currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  • As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, renal transplant and active bleeding diseases) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
  • Any concurrent anti-cancer treatment.
  • Active infection including tuberculosis, and .

INFORMATION FOR TRIAL PARTICIPANTS

Participants cannot join the trial if they:

  • Have uncontrolled cancer that has spread to the brain or the spinal cord
  • Have received certain treatments for cancer in the past but the cancer came back within 1 year
  • Had certain types of tumors in the past, which the study doctors think could come back
  • Are currently taking any treatment for cancer or are taking medications or supplements that affect certain proteins in the body
  • Have any major health problem, infection, or surgery that could make it difficult or dangerous to participate in this trial, such as tuberculosis, , heart problems, or a kidney transplant

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,371 participants (actual)

Study arms

  • Experimental
    AZD9833 + palbociclib

    The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (1 mg, PO, once daily)

    Drug: AZD9833 · Drug: Anastrozole placebo · Drug: Palbociclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist

  • Active comparator
    Anastrozole + palbociclib

    The patients will recieve Anastrozole (1 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)

    Drug: Anastrozole · Drug: AZD9833 placebo · Drug: Palbociclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist

Interventions

  • Dosage formulation: AZD9833 tablets will be administered orally

  • Dosage formulation: Anastrozole tablets will be administered orally.

  • DrugAnastrozole placebo

    Dosage formulation: anastrozole placebo tablets will be administrated orally.

  • DrugAZD9833 placebo

    Dosage formulation: AZD9833 placebo tablets will be administrated orally.

  • Dosage formulation: palbociclib tablets/capsules will be administered orally

  • Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1

    PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST) or death.

    Time frame: From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)

Secondary outcomes

  1. Overall survival (OS)

    The OS is defined as the time from randomization to death due to any cause.

    Time frame: From randomization until the date of death due to any cause (up to 8 years)

  2. Second progression-free survival (PFS2)

    Time to second progression or death (PFS2) will be defined as the time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

    Time frame: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (up to 5 years)

  3. Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1

    ORR is defined as the proportion of patients who have a CR or partial response, as determined by the investigator at local site per RECIST 1.1.

    Time frame: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (up to 5 years)

  4. Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1

    The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.

    Time frame: From the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)

  5. Time to chemotherapy (TTC)

    Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.

    Time frame: From randomization until the earlier of the start date of chemotherapy or death due to any cause (up to 5 years)

  6. Time to first subsequent anti-cancer therapy (TFST)

    TFST is defined as time from randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.

    Time frame: From randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause (up to 5 years)

  7. Clinical benefit rate at 24 weeks (CBR24)

    CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for at least 23 weeks after randomization (to allow for an early assessment within the assessment window).

    Time frame: At least 23 weeks after randomisation

  8. Time to second subsequent therapy (TSST)

    TSST is defined as time from randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

    Time frame: From randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (up to 5 years)

  9. Plasma concentration of AZD9833 at specified timepoints

    To assess the steady state PK of AZD9833 in combination with palbociclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.

    Time frame: on Day 15

  10. Change from baseline in EORTC QLQ-C30 scale scores

    Change from baseline in EORTC QLQ-C30 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score.

    Time frame: From baseline to 24 weeks post progression (up to approximately 5 years)

  11. Change from baseline in EORTC QLQ-BR45 scale scores

    Change from baseline in EORTC QLQ-BR45 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score.

    Time frame: From baseline to 24 weeks post progression (up to approximately 5 years)

07

Study locations

263 sites
  • Research Site
    Mobile, Alabama 36604, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Harbor City, California 90710, United States
  • Research Site
    Solvang, California 93463, United States
  • Research Site
    Lone Tree, Colorado 80124, United States
  • Research Site
    Fort Myers, Florida 33901-8101, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Indianapolis, Indiana 46256, United States
  • Research Site
    Baton Rouge, Louisiana 70809, United States
  • Research Site
    Silver Spring, Maryland 20904, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Hattiesburg, Mississippi 39401, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    West Columbia, South Carolina 29169, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Kennewick, Washington 99336, United States
  • Research Site
    Renton, Washington 98055, United States
  • Research Site
    Morgantown, West Virginia 26505, United States
  • Research Site
    Feldkirch, 6807, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1130, Austria
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4109, Bulgaria
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1H7, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Concepción, 4070196, Chile
  • Research Site
    La Serena, 1720430, Chile
  • Research Site
    Santiago, 7630370, Chile
  • Research Site
    Santiago, 8241479, Chile
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Dalian, 116011, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Guiyang, 550004, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430000, China
  • Research Site
    Wuhan, 430040, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Hořovice, 268 01, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Nový Jičín, 741 01, Czechia
  • Research Site
    Prague, 100 34, Czechia
  • Research Site
    Prague, 140 00, Czechia
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    Besançon, 25030, France
  • Research Site
    Bordeaux, 33030, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Caen, 14076, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Le Mans, 72000, France
  • Research Site
    Lille, 59000, France

Showing the first 100 of 263 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2026, 64 months.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 64 months is above that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jun 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2020
First posted
Jan 15, 2021
StartActual
Jan 28, 2021
Primary completionActual
Jun 26, 2026was Aug 2026
CompletionEst.
Feb 1, 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Site · Toluca, Mexico
Show 1 removed
  • Research Site · Estado de México, Mexico
Sep 28, 2026
Primary completion
Aug 24, 2026→Jun 26, 2026 (actual)
Sep 28, 2026
Enrollment
1370→1371
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    1 site added, 1 site removed
    Show site
    • Research Site · Toluca, Mexico
    Show 1 removed
    • Research Site · Estado de México, Mexico
    Primary completion Aug 24, 2026→Jun 26, 2026 (now actual)
    Enrollment 1370→1371
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04711252
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Jan 28, 2021
Primary completion
Jun 26, 2026
Completion
Feb 1, 2029 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion